Improving chemotherapy response of immunologically cold high-grade serous ovarian cancer with loss of PTEN using STING agonist.

被引：0
|
作者：
Shakfa, Noor [1 ]
Lightbody, Elizabeth [1 ]
Afriyie-Asante, Afrakoma [1 ]
Kannen, Vinicius [1 ]
Koti, Madhuri [1 ]
机构：
[1] Queens Univ, Kingston, ON, Canada
来源：
CLINICAL CANCER RESEARCH | 2020年 / 26卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B78
引用
收藏
页码：120 / 120
页数：1
相关论文
共 50 条
  • [1] STING agonist treatment increases response to chemotherapy and immune checkpoint blockade therapy in a syngeneic murine model of high-grade serous ovarian cancer
    Ghaffari, Abdi
    Peterson, Nichole
    Khalaj, Kasra
    Robinson, Andrew
    Francis, Julie-Ann
    Koti, Madhuri
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [2] STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer
    Abdi Ghaffari
    Nichole Peterson
    Kasra Khalaj
    Natasha Vitkin
    Andrew Robinson
    Julie-Ann Francis
    Madhuri Koti
    [J]. British Journal of Cancer, 2018, 119 : 440 - 449
  • [3] STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer
    Ghaffari, Abdi
    Peterson, Nichole
    Khalaj, Kasra
    Vitkin, Natasha
    Robinson, Andrew
    Francis, Julie-Ann
    Koti, Madhuri
    [J]. BRITISH JOURNAL OF CANCER, 2018, 119 (04) : 440 - 449
  • [4] Transcriptomic profiles of response to neoadjuvant chemotherapy in patients with high-grade serous ovarian cancer
    Lee, Sanghoon
    Zhao, Li
    Fleming, Nicole D.
    Celestino, Joseph
    Hajek, Richard A.
    Morgan, Margaret B.
    Liu, Yan
    Westin, Shannon N.
    Jazaeri, Amir A.
    Liu, Jinsong
    Zhang, Jianhua
    Futreal, P. Andrew
    Sood, Anil K.
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [5] Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
    Arend, Rebecca C.
    Londono, Angelina I.
    Montgomery, Allison M.
    Smith, Haller J.
    Dobbin, Zachary C.
    Katre, Ashwini A.
    Martinez, Alba
    Yang, Eddy S.
    Alvarez, Ronald D.
    Huh, Warner K.
    Bevis, Kerri S.
    Straughn, J. Michael, Jr.
    Estes, Jacob M.
    Novak, Lea
    Crossman, David K.
    Cooper, Sara J.
    Landen, Charles N.
    Leath, Charles A., III
    [J]. MOLECULAR CANCER RESEARCH, 2018, 16 (05) : 813 - 824
  • [6] Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma
    Montgomery, A. M.
    Crossman, D. K.
    Yang, E. S.
    Alvarez, R. D.
    Huh, W. K.
    Bevis, K. S.
    Straughn, J. M., Jr.
    Leath, C. A., III
    Arend, R. C.
    [J]. GYNECOLOGIC ONCOLOGY, 2017, 145 : 12 - 13
  • [7] Determinants of resistance and response in high-grade serous ovarian cancer
    Bowtell, David D. L.
    [J]. CLINICAL CANCER RESEARCH, 2016, 22
  • [8] The tumor immune microenvironment modulates response to chemotherapy in high-grade serous epithelial ovarian cancer
    Koti, Madhuri
    Edwards, Andrew
    Squire, Jeremy A.
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [9] Ovarian Cancer Response Scoring (OCRS): Validation of a system to quantify histopathological response to neoadjuvant chemotherapy in high-grade serous ovarian cancer
    Singh, N.
    Said, I.
    Faruqi, A.
    Gilks, B.
    Le, N.
    Boehm, S.
    [J]. VIRCHOWS ARCHIV, 2014, 465 : S40 - S40
  • [10] Acquired chemotherapy resistance in high-grade serous ovarian cancer patients.
    Christie, Elizabeth L.
    Beach, Jessica
    Etemadmoghadam, Dariush
    Garsed, Dale
    Patch, Ann-Marie
    Fereday, Sian
    Pattnaik, Swetansu
    Brady, Samuel
    Bild, Andrea
    Bowtell, David D. L.
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (15) : 20 - 20
12345